Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Abstract
Autologous hematopoietic cell transplantation (HCT) remains the standard of care for most patients with refractory or relapsed Hodgkin lymphoma (HL). However, the role of allogeneic HCT for this patient population is less defined. In retrospective analyses, allogeneic HCT with myeloablative conditioning confers lower relapse rates compared to autologous HCT but the higher nonrelapse mortality (NRM) offsets any survival benefit. This observed prohibitive NRM has thus fueled the increasing use of allogeneic HCT with reduced intensity conditioning (RIC) especially for patients who have failed a prior autologous HCT. Results with RIC allogeneic HCT appear promising with chemosensitive patients faring the best. Donor leukocyte infusions has been reported to induce durable remissions in relapsed HL patients even in patients who did not receive prior cytoreductive therapy which thus lends support to a graft versus HL effect.
View details for DOI 10.1080/10428190802304974
View details for Web of Science ID 000260326500006
View details for PubMedID 18949609